Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 5, Pages 1101
Publisher
MDPI AG
Online
2020-04-29
DOI
10.3390/cancers12051101
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Therapeutic implications of germline genetic findings in cancer
- (2019) Subotheni Thavaneswaran et al. Nature Reviews Clinical Oncology
- Genomic signatures predict the immunogenicity of BRCA-deficient breast cancer
- (2019) Adam A Kraya et al. CLINICAL CANCER RESEARCH
- Germline-Focused Analysis of Tumour-Only Sequencing: Recommendations from the ESMO Precision Medicine Working Group
- (2019) D Mandelker et al. ANNALS OF ONCOLOGY
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
- (2019) Jason K. Sicklick et al. NATURE MEDICINE
- The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta‐analysis
- (2019) Eliana Rulli et al. CANCER
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
- (2019) Andrea Forschner et al. Journal for ImmunoTherapy of Cancer
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Toward understanding the origin and evolution of cellular organisms
- (2019) Minoru Kanehisa PROTEIN SCIENCE
- LBA15_PRA phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
- (2019) K Fizazi et al. ANNALS OF ONCOLOGY
- Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond
- (2018) Jeffrey E. Gershenwald et al. ANNALS OF SURGICAL ONCOLOGY
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
- (2018) J Mateo et al. ANNALS OF ONCOLOGY
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Development of PARP and Immune-Checkpoint Inhibitor Combinations
- (2018) Ross A Stewart et al. CANCER RESEARCH
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- New approach for understanding genome variations in KEGG
- (2018) Minoru Kanehisa et al. NUCLEIC ACIDS RESEARCH
- Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study
- (2017) Arezou A. Ghazani et al. GENETICS IN MEDICINE
- Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing
- (2017) Diana Mandelker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing
- (2017) Qianying Zhao et al. Journal of Gynecologic Oncology
- Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
- (2017) Chan-Young Ock et al. Nature Communications
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol
- (2016) F. Meric-Bernstam et al. ANNALS OF ONCOLOGY
- RECIST 1.1—Update and clarification: From the RECIST committee
- (2016) Lawrence H. Schwartz et al. EUROPEAN JOURNAL OF CANCER
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors
- (2016) D. Williams Parsons et al. JAMA Oncology
- Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
- (2016) Kasmintan A. Schrader et al. JAMA Oncology
- Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms
- (2016) Maria Schwaederle et al. JAMA Oncology
- Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
- (2015) M. A. Wilson et al. CLINICAL CANCER RESEARCH
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
- (2015) Sue Richards et al. GENETICS IN MEDICINE
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- (2015) Ariel Lopez-Chavez et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
- (2015) Matthew T Chang et al. NATURE BIOTECHNOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD8 Memory Cells Develop Unique DNA Repair Mechanisms Favoring Productive Division
- (2015) Alessia Galgano et al. PLoS One
- An update on PARP inhibitors for the treatment of cancer
- (2015) Marcia Hall et al. OncoTargets and Therapy
- Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads
- (2014) Hongshan Jiang et al. BMC BIOINFORMATICS
- Quiescent Hematopoietic Stem Cells Accumulate DNA Damage during Aging that Is Repaired upon Entry into Cell Cycle
- (2014) Isabel Beerman et al. Cell Stem Cell
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fast and accurate long-read alignment with Burrows–Wheeler transform
- (2010) Heng Li et al. BIOINFORMATICS
- Homologous Recombination Is Necessary for Normal Lymphocyte Development
- (2008) L. B. Caddle et al. MOLECULAR AND CELLULAR BIOLOGY
- DNA double-strand breaks activate a multi-functional genetic program in developing lymphocytes
- (2008) Andrea L. Bredemeyer et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now